Erythroid Lineages from Pluripotent Cells
Summary
USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.
What changed
USPTO published patent application US20260097074A1 titled 'Erythroid Lineages Derived from Pluripotent Cells' filed by Dhvanit Shah on October 5, 2023. The application discloses methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells from human induced pluripotent stem cells (iPSCs). The invention provides efficient ex vivo processes for developing these lineages and isolated cell compositions for cell therapy.
Affected parties including biotechnology companies, pharmaceutical developers, and researchers working on cell-based therapies involving hematopoietic lineages should review this published application to assess potential freedom-to-operate considerations and patent landscape implications for their own product development programs.
What to do next
- Monitor for patent prosecution updates
- Review freedom-to-operate implications for related cell therapy research
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ERYTHROID LINEAGES DERIVED FROM PLURIPOTENT CELLS
Application US20260097074A1 Kind: A1 Apr 09, 2026
Inventors
Dhvanit Shah
Abstract
The present disclosure, in various aspects and embodiments, provides methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), and megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells. In various embodiments, the invention provides for efficient ex vivo processes for developing such hematopoietic lineages, including but not limited to progenitor erythroblast cells and erythroblast cell lineages, from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or bone marrow. The present invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.
CPC Classifications
A61K 35/14 C12N 5/0647 C12N 15/86 C12N 2500/24 C12N 2500/32 C12N 2501/105 C12N 2501/115 C12N 2501/125 C12N 2501/14 C12N 2501/155 C12N 2501/165 C12N 2501/2306 C12N 2501/2311 C12N 2506/45 C12N 2710/10043
Filing Date
2023-10-05
Application No.
19117852
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.